Sanofi SA (SASY.PA)

SASY.PA on Paris Stock Exchange

88.85EUR
1 Oct 2014
Price Change (% chg)

€-0.71 (-0.79%)
Prev Close
€89.56
Open
€89.15
Day's High
€89.74
Day's Low
€88.76
Volume
2,560,482
Avg. Vol
2,621,039
52-wk High
€89.95
52-wk Low
€68.29

SASY.PA

Chart for SASY.PA

About

Sanofi, formerly Sanofi-Aventis is a global and diversified healthcare company. The Company discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi focuses on the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, rare diseases, consumer... (more)

Overall

Beta: 0.54
Market Cap (Mil.): €118,523.80
Shares Outstanding (Mil.): 1,323.40
Dividend: 2.80
Yield (%): 3.13

Financials

  SASY.PA Industry Sector
P/E (TTM): 28.86 33.37 34.07
EPS (TTM): 3.10 -- --
ROI: 5.31 18.15 17.40
ROE: 7.69 18.85 18.25
Search Stocks

Sanofi-Regeneron drug has positive trial results in chronic sinusitis

PARIS - An experimental drug from Sanofi and Regeneron significantly reduced congestion in in a mid-stage trial on patients with chronic sinusitis with nasal polyps, a condition poorly controlled by existing drugs, the companies said on Tuesday.

30 Sep 2014

UPDATE 1-Sanofi-Regeneron drug has positive trial results in chronic sinusitis

* Dupilumab significantly reduced nasal polyps and congestion

30 Sep 2014

Sanofi posts positive results for drug in chronic sinusitis

PARIS, Sept 30 - Sanofi and its U.S. partner Regeneron on Tuesday unveiled positive mid-stage trial results for their experimental drug dupilumab in patients with chronic sinusitis with nasal polyps.

30 Sep 2014

US STOCKS-MannKind, Magnum Hunter among premarket actives

NEW YORK, Sept 25 - MannKind Corp shares were among the most actively traded in premarket on Thursday, after the company said it had closed a licensing agreement with Sanofi for the development and commercialization of its inhaled insulin product.

25 Sep 2014

BRIEF-Genfit signs extension to shared research agreement with Sanofi

* Signs extension to shared research agreement with Sanofi until May 2015

23 Sep 2014

Sanofi unveils heart disease partnership with MyoKardia

PARIS, Sept 17 - French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases.

17 Sep 2014

Sanofi aims to grow Genzyme unit with new drugs and acquisitions

PARIS - (This story corrects the Sept.11 story. In the 10th paragraph, the quote should be attributed to Bill Sibold, not Mike Panzara)

13 Sep 2014

Sanofi aims to grow Genzyme unit with new drugs and acquisitions

PARIS - Sanofi rare disease unit Genzyme hopes to become a leader in the multiple sclerosis (MS) field with the help of new products developed in-house but also through acquisitions, senior Genzyme executives told Reuters.

11 Sep 2014

Sanofi says MS drug Lemtrada shows sustained effect on disease

PARIS - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.

11 Sep 2014

Sanofi says MS drug Lemtrada shows sustained effect on disease

PARIS, Sept 11 - Sanofi rare disease unit Genzyme said its Lemtrada multiple sclerosis (MS) drug showed continued efficacy for four years in more than two thirds of patients and that no new safety risks had been identified in its latest studies.

11 Sep 2014

Earnings vs. Estimates

Search Stocks